What to ask:
“I want to join this clinical study to access FDA-approved off-guideline cancer drugs.”
One-page email/handout, with links:
Cancer Commons has launched a clinical study that enables advanced cancer patients, who have exhausted effective treatments, to access FDA-approved off-guideline drugs not available under the NCCN Guidelines.
This observational study employs diagnostic tests, both genomic and functional, to pinpoint promising off-guideline drugs for each study participant. The Clinical Study Team will compile a comprehensive analysis of the evidence from the diagnostic tests and scientific literature regarding the potential effectiveness of these off-guideline drugs. You will receive this analysis to determine if the off-guideline drugs could be beneficial for your patient.
The Clinical Study Team will deliver the report to the patient’s health insurer (Medicare or private) as a medical necessity request for reimbursement. A key responsibility of the Clinical Study Team is to minimize the work you need to do to convince insurance to cover the off-guideline drugs.
There are no predetermined study sites. As the treating oncologist, you can administer treatment to the patient at your current hospital.
For more information, please visit www.cancercommons.org/CCCS001
